Company profile
Intellia Therapeutics, Inc.
NASDAQ: NTLA · Healthcare · Biotechnology
#395 of 1,418 Healthcare companies by revenue63rd-percentile growth
EA Score
57CFH 50DQ 64GM 58SS 70
v0.1 · 65/100 weight · provisional
↑ market scale, balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$59.5M
Rev growth YoY (TTM)
+12.6%
Net income (FY)
-$412.7M
Employees
377
as of 2026-08-09
Market cap
$1.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$67.7M$67.7M2025
Net income-$412.7M-$412.7M2025
Operating income-$441.0M-$441.0M2025
Total assets$842.1M$842.1M2025
Liabilities$170.7M$170.7M2025
Equity$671.4M$671.4M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Intellia Therapeutics, Inc.’s revenue?
Intellia Therapeutics, Inc. booked $67.7M in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a -609.9% net margin.
Peers · Healthcare
Personalis, Inc.59CRockwell Medical, Inc.60CVir Biotechnology, Inc.48DKura Oncology, Inc.39DPraxsyn Corporation——Pro-Dex, Inc.86ANeighbors
Middlesex →Key facts
CEOJohn Leonard
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: NTLA
Employees377
IPO date2016-05-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.